摘要
背景与目的:染色质结构是一个最重要的特征,区别癌细胞与正常细胞组织学。染色质重塑蛋白调节染色质结构和高机动组(HMGA1)蛋白是最丰富的,非组蛋白染色质重塑蛋白是在癌细胞中发现的。这些蛋白质包括HMGA1a/HMGA1b 亚型,导致选择性剪接的mRNA。HMGA1基因是在癌症中的过度表达和肿瘤预后不良效果的高度预测。HMGA1在胚胎发育和出生后的成体干细胞也高表达。HMGA1在培养细胞恶性转化而带动的过度表达,抑制致癌基因HMGA1块干细胞和肿瘤干细胞的特性。基因的转基因小鼠死于恶性肿瘤,表明表达的失调导致在体内蛋白的癌症。HMGA1也是体细胞重编程为诱导多能干细胞的所需。HMGA1蛋白的功能作为辅助转录因子,弯曲的染色质和引诱其他转录因子的DNA。他们诱导致癌性转化通过激活或抑制特定基因参与了这一过程和HMGA1“转录”的出现。虽然之前的研究发现HMGA1强力致癌的特性,我们才刚刚开始通过HMGA1功能了解的分子机制。在这篇综述中,我们总结了可能的下游基因的转录受目标HMGA1列表。我们还简要地讨论研究连接HMGA1对阿尔茨海默氏症和糖尿病。 结论:HMGA1功能进一步阐明导致癌症可能与异常HMGA1的表达相关的其他疾病的新的治疗策略。
关键词: 高迁移率A1组,HMGA、染色质、癌症、肿瘤的进展、转移、基因、肿瘤干细胞、胚胎干细胞。
Current Molecular Medicine
Title:The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development
Volume: 16 Issue: 4
Author(s): T.F. Sumter, L. Xian, T. Huso, M. Koo, Y.-T. Chang, T.N. Almasri, L. Chia, C. Inglis, D. Reid, L.M.S. Resar
Affiliation:
关键词: 高迁移率A1组,HMGA、染色质、癌症、肿瘤的进展、转移、基因、肿瘤干细胞、胚胎干细胞。
摘要: Background & Objectives: Chromatin structure is the single most important feature that distinguishes a cancer cell from a normal cell histologically. Chromatin remodeling proteins regulate chromatin structure and high mobility group A (HMGA1) proteins are among the most abundant, nonhistone chromatin remodeling proteins found in cancer cells. These proteins include HMGA1a/HMGA1b isoforms, which result from alternatively spliced mRNA. The HMGA1 gene is overexpressed in cancer and high levels portend a poor prognosis in diverse tumors. HMGA1 is also highly expressed during embryogenesis and postnatally in adult stem cells. Overexpression of HMGA1 drives neoplastic transformation in cultured cells, while inhibiting HMGA1 blocks oncogenic and cancer stem cell properties. Hmga1 transgenic mice succumb to aggressive tumors, demonstrating that dysregulated expression of HMGA1 causes cancer in vivo. HMGA1 is also required for reprogramming somatic cells into induced pluripotent stem cells. HMGA1 proteins function as ancillary transcription factors that bend chromatin and recruit other transcription factors to DNA. They induce oncogenic transformation by activating or repressing specific genes involved in this process and an HMGA1 “transcriptome” is emerging. Although prior studies reveal potent oncogenic properties of HMGA1, we are only beginning to understand the molecular mechanisms through which HMGA1 functions. In this review, we summarize the list of putative downstream transcriptional targets regulated by HMGA1. We also briefly discuss studies linking HMGA1 to Alzheimer’s disease and type-2 diabetes.
Conclusion: Further elucidation of HMGA1 function should lead to novel therapeutic strategies for cancer and possibly for other diseases associated with aberrant HMGA1 expression.
Export Options
About this article
Cite this article as:
T.F. Sumter, L. Xian, T. Huso, M. Koo, Y.-T. Chang, T.N. Almasri, L. Chia, C. Inglis, D. Reid, L.M.S. Resar , The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development, Current Molecular Medicine 2016; 16 (4) . https://dx.doi.org/10.2174/1566524016666160316152147
DOI https://dx.doi.org/10.2174/1566524016666160316152147 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Marfan Syndrome and Related Heritable Thoracic Aortic Aneurysms and Dissections
Current Pharmaceutical Design Cell Death and microRNAs in Cholestatic Liver Diseases: Update on Potential Therapeutic Applications
Current Drug Targets Hepatic Effects of Duloxetine-II: Spontaneous Reports and Epidemiology of Hepatic Events
Current Drug Safety Notch Signaling in Normal and Disease States: Possible Therapies Related to Glycosylation
Current Molecular Medicine Enzymes as Target Antigens of Liver-Specific Autoimmunity: The Case of Cytochromes P450s
Current Medicinal Chemistry Human Induced Pluripotent Stem Cells for Inherited Cardiovascular Diseases Modeling
Current Stem Cell Research & Therapy Personalized and Regenerative Medicine for Liver Diseases
Current Stem Cell Research & Therapy Functional Chemical Groups that May Likely Become a Source for the Synthesis of Novel Central Nervous System (CNS) Acting Drugs
Central Nervous System Agents in Medicinal Chemistry Autoimmune Hepatitis: A Childhood Disease
Current Pediatric Reviews Recent Developments in Group I Metabotropic Glutamate Receptor Allosteric Modulators for the Treatment of Psychiatric and Neurological Disorders (2014-May 2015)
Current Topics in Medicinal Chemistry Similar Mechanisms Regulated by γ-Secretase are Involved in Both Directions of the Bi-Directional Notch-Delta Signaling Pathway as well as Play a Potential Role in Signaling Events Involving Type 1 Transmembrane Proteins
Current Stem Cell Research & Therapy Orally Administrated Small Molecule Drugs with Intestine Targeted Profile: Recent Development and Prospects
Current Medicinal Chemistry Congenital Scoliosis (Mini-review)
Current Pediatric Reviews Past and Recent Progress of Molecular Imaging Probes for β-Amyloid Plaques in the Brain
Current Medicinal Chemistry Medical Treatment of Aortic Aneurysms in Marfan Syndrome and other Heritable Conditions
Current Cardiology Reviews Neurocognitive Monitoring and Care During Pediatric Cardiopulmonary Bypass — Current and Future Directions
Current Cardiology Reviews Classical Neurotransmitters and Neuropeptides Involved in Parkinson's Disease: Focus on Anti-Parkinsonian Drugs
Current Drug Therapy Insight γ-Secretase: Structure, Function, and Role in Alzheimer’s Disease
Current Drug Targets Current Options for Treatment of End-Stage Liver Disease in Children
Current Pediatric Reviews Group I Metabotropic Glutamate Receptor Signalling and its Implication in Neurological Disease
CNS & Neurological Disorders - Drug Targets